.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01E_ProteinKinaseInhibitors.L01EA02_Dasatinib.Dasatinib .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01E_ProteinKinaseInhibitors.L01EA02_Dasatinib.Dasatinib| name: | Dasatinib |
| ATC code: | L01EA02 | route: | oral |
| n-compartments | 2 |
Dasatinib is an oral tyrosine kinase inhibitor used in the treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). It is approved for use in adults and children and acts by inhibiting BCR-ABL and other kinases.
Pharmacokinetic parameters observed in adult patients with chronic myeloid leukemia (CML) after oral administration.
Ishida, Y, et al., & Ito, S (2016). Pharmacokinetics and pharmacodynamics of dasatinib in the chronic phase of newly diagnosed chronic myeloid leukemia. European journal of clinical pharmacology 72(2) 185–193. DOI:10.1007/s00228-015-1968-y PUBMED:https://pubmed.ncbi.nlm.nih.gov/26507546
Iwamoto, T, et al., & Katayama, N (2019). Evaluation of Medication Adherence and Pharmacokinetics of Dasatinib for Earlier Molecular Response in Japanese Patients With Newly Diagnosed Chronic Myeloid Leukemia: A Pilot Study. Therapeutic drug monitoring 41(5) 575–581. DOI:10.1097/FTD.0000000000000639 PUBMED:https://pubmed.ncbi.nlm.nih.gov/31008998
Gibson, EG, et al., & Stewart, CF (2021). Population pharmacokinetic analysis of crizotinib in children with progressive/recurrent high-grade and diffuse intrinsic pontine gliomas. Cancer chemotherapy and pharmacology 88(6) 1009–1020. DOI:10.1007/s00280-021-04357-4 PUBMED:https://pubmed.ncbi.nlm.nih.gov/34586478